Core Insights - OrthoPediatrics Corp. achieved an all-time high revenue of $236.1 million for the full year 2025, reflecting a growth of 15% compared to the previous year [1][6] - The company initiated guidance for record Adjusted EBITDA in 2026, projecting revenue between $262 million and $266 million, which represents an 11% to 13% growth compared to 2025 [3][4] Recent Business and Financial Highlights - In 2025, OrthoPediatrics helped over 37,500 children in the fourth quarter alone, totaling nearly 1.3 million since inception [4][6] - The preliminary unaudited net revenue for the fourth quarter of 2025 was $61.3 million, marking a 16% increase from $52.7 million in Q4 2024 [6] - Domestic net revenue for 2025 is expected to be $186.2 million, indicating a 16% annual growth, while international net revenue is projected at $49.9 million, reflecting a 15% annual growth [6] - The company generated approximately $6.0 to $7.0 million in free cash flow for Q4 2025, resulting in total free cash flow usage for the year being over 50% lower than in 2024 [6] Strategic Initiatives - The Trauma and Deformity and Scoliosis implant businesses have effectively executed strategies to gain market share, drive revenue, and improve profitability [4] - The specialty bracing (OPSB) business is identified as a significant market opportunity and a strategic catalyst for enhancing customer relationships, proving to be a capital-efficient driver of revenue and earnings [4]